5-tert-butyl-2,3-dihydro-2-methylbenzofuran | 3199-36-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 香豆素
• 英文名称: 5-tert-butyl-2,3-dihydro-2-methylbenzofuran
• 英文别名: 6-tert.-Butyl-2-methyl-2,3-dihydro-benzofuran；2-Methyl-5-tert.-butyl-cumaran；5-tert-butyl-2-methyl-2,3-dihydro-benzofuran；5-Tert-butyl-2-methyl-2,3-dihydro-1-benzofuran；5-tert-butyl-2-methyl-2,3-dihydro-1-benzofuran
• CAS: 3199-36-8
• 化学式: C₁₃H₁₈O
• 分子量: 190.285
• InChiKey: GZMGNYKWEWIMHP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  allyl p-cymyl ether 在 三苯基膦氯金 、 silver trifluoromethanesulfonate 作用下， 以 甲苯 为溶剂， 以68%的产率得到5-tert-butyl-2,3-dihydro-2-methylbenzofuran
  参考文献：
  名称：

  金(I)-催化芳基烯丙基醚合成二氢苯并呋喃

  摘要：

  由芳基烯丙基醚形成二氢苯并呋喃由原位生成的 PPh 3 AuOTf 催化。该反应似乎是通过克莱森重排进行的，然后将所得苯酚加成到烯丙基上。

  DOI：

  10.1055/s-2006-932491

文献信息

• Gold(I)-Catalyzed Synthesis of Dihydrobenzofurans from Aryl Allyl Ethers
  作者：Chuan He、Nicholas Reich、Cai-Guang Yang、Zhangjie Shi

  DOI：10.1055/s-2006-932491

  日期：——

  Formation of dihydrobenzofurans from aryl allyl ethers was catalyzed by in situ generated PPh 3 AuOTf. This reaction appears to proceed by a Claisen rearrangement, followed by addition of the resulting phenol to the allyl group.

  由芳基烯丙基醚形成二氢苯并呋喃由原位生成的 PPh 3 AuOTf 催化。该反应似乎是通过克莱森重排进行的，然后将所得苯酚加成到烯丙基上。
• Amine Derivatives as Potassium Channel Blockers
  申请人：Harvey Andrew

  公开号：US20140336198A1

  公开（公告）日：2014-11-13

  The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis, pharmaceutical compositions containing these compounds and methods for their preparation.

  本发明涉及用于调节细胞中钾通道活性的化合物，特别是用于调节T细胞中发现的Kv1.3通道活性的化合物。本发明还涉及使用这些化合物治疗或预防自身免疫和炎症性疾病，包括多发性硬化症，含有这些化合物的制药组合物以及它们的制备方法。
• Bile acid derivatives as FXR agonists and methods of use thereof
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US10472386B2

  公开（公告）日：2019-11-12

  The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, prodrugs and esters thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.

  本发明提供了由式 I 代表的化合物或其药学上可接受的盐、原药和酯，本发明还提供了包含这些化合物的药物组合物以及使用这些化合物治疗 FXR 介导或 TGR5 介导的疾病或病症的方法。
• Sen; Rastogi, Journal of the Indian Chemical Society, 1953, vol. 30, p. 355,357
  作者：Sen、Rastogi

  DOI：——

  日期：——
• AMINE DERIVATIVES AS POTASSIUM CHANNEL BLOCKERS
  申请人：Bionomics Limited

  公开号：US20170088519A1

  公开（公告）日：2017-03-30

  The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis, pharmaceutical compositions containing these compounds and methods for their preparation.